• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A basic research for novel treatment for castration resistant prostate cancer via LSD1 and autophagy

Research Project

Project/Area Number 16K11023
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Urology
Research InstitutionNagoya City University

Principal Investigator

ETANI TOSHIKI  名古屋市立大学, 大学院医学研究科, 助教 (30600754)

Co-Investigator(Kenkyū-buntansha) 河合 憲康  名古屋市立大学, 大学院医学研究科, 准教授 (20254279)
内木 綾  名古屋市立大学, 大学院医学研究科, 高度医療教育研究センター講師 (20509236)
安藤 亮介  名古屋市立大学, 大学院医学研究科, 講師 (30381867)
飯田 啓太郎  名古屋市立大学, 大学院医学研究科, 臨床研究医 (30713945)
安井 孝周  名古屋市立大学, 大学院医学研究科, 教授 (40326153)
内木 拓  名古屋市立大学, 大学院医学研究科, 講師 (50551272)
Research Collaborator TAKAHASHI satoru  
SUZUKI takayoshi  
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
KeywordsLSD1 / エピゲノム / 前立腺癌 / アポトーシス / p21 / LSD1発現変化 / オートファジー / 去勢抵抗性前立腺癌 / 癌 / 細胞・組織 / マイクロアレイ
Outline of Final Research Achievements

The CRPC cell lines, 22Rv1, PC3, and PCai1CS, were treated with NCL1, and LSD1 expression and cell viability were assessed. CRPC cells showed strong LSD1 expression, and cell viability was decreased by NCL1 in a dose-dependent manner. In western blotting and flow cytometry, NCL1 also dose-dependently induced caspase-dependent apoptosis. In addition, stimulation of autophagy was observed in NCL1-treated 22Rv1 cells by transmission electron microscopy and LysoTracker analysis. In ex vivo analysis, castrated nude mice were injected subcutaneously with PCai1 cells and intraperitoneally with NCL1. Tumor volume was found to be reduced with no adverse effects in NCL1-treated mice compared with controls. Finally, immunohistochemical analysis using consecutive human specimens in pre- and post-androgen deprivation therapy demonstrated that LSD1 expression levels in CRPC were very high, and identical to levels observed in previously examined prostate biopsy specimens.

Academic Significance and Societal Importance of the Research Achievements

前立腺癌は世界で最も多くみられるがんの一つとなり、本邦でもその発生は増加の一途をたどっている。前立腺癌は初期治療に抵抗性となると治癒が困難となり、新規治療法の開発が強く望まれている。私たちはエピゲノム酵素のひとつであるLSD1のその治療標的としての意義に着目し、各種の泌尿器癌で研究を進めてきた。本研究は、これまでの去勢感受性前立腺癌へのLSD1阻害剤の効果の研究に引き続き、臨床でももっとも問題となる去勢抵抗性前立腺癌へのLSD1阻害剤の効果を明らかにした報告であり、LSD1阻害剤およびオートファジー阻害剤の前立腺癌新規治療法としての可能性を大きく推進するものであると考えられる。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (11 results)

All 2019 2018 2017 2016

All Journal Article (2 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (9 results) (of which Int'l Joint Research: 3 results,  Invited: 3 results)

  • [Journal Article] NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses castration-resistant prostate cancer growth via regulation of apoptosis and autophagy.2019

    • Author(s)
      Etani T, Naiki T, Naiki-Ito A, Suzuki T, Iida K, Nozaki S, Kato H, Yagayasu Y, Suzuki S, Kawai N, Yasui T, Takahashi S.
    • Journal Title

      J Clin Med.

      Volume: 8 Issue: 4 Pages: 442-442

    • DOI

      10.3390/jcm8040442

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] ヒストン脱メチル化酵素LSD1の新規阻害剤NCL1の前立腺癌に対する抗腫瘍効果2017

    • Author(s)
      .惠谷 俊紀、内木 拓、飯田 啓太郎、安藤 亮介、河合 憲康、戸澤 啓一、鈴木 孝禎、高橋 智、安井 孝周
    • Journal Title

      NAGOYA MEDICAL JOURNAL

      Volume: 55 Pages: 169-174

    • Related Report
      2017 Research-status Report
  • [Presentation] Novel selective lysine specific demethylase 1 inhibitors effectively impair castration resistant prostate cancer growth.2019

    • Author(s)
      Etani Toshiki, Naiki Taku, Nagai Takashi, Nozaki Satoshi, Iida Keitaro, Ando Ryosuke, Kawai Noriyasu, Tozawa Keiichi, Suzuki Takayoshi, Yasui Takahiro
    • Organizer
      34th Anuual EAU Congress
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] エピゲノム変化を介した去勢抵抗性前立腺癌におけるオートファジー制御メカニズムの解明と新規治療法の開発2018

    • Author(s)
      惠谷 俊紀、内木 拓、内木 綾、飯田 啓太郎、安藤 亮介、河合 憲康、高橋 智、鈴木 孝禎、安井 孝周
    • Organizer
      第106回日本泌尿器科学会総会
    • Related Report
      2018 Annual Research Report
    • Invited
  • [Presentation] Novel selective lysine specific demethylase 1 inhibitors effectively impair castration resistant prostate cancer growth.2018

    • Author(s)
      Etani Toshiki, Naiki Taku, Nagai Takashi, Iida Keitaro, Ando Ryosuke, Kawai Noriyasu, Tozawa Keiichi, Suzuki Takayoshi, Yasui Takahiro
    • Organizer
      American Urological Association Annual Meeting 2018
    • Related Report
      2018 Annual Research Report
    • Int'l Joint Research
  • [Presentation] リジン特異的脱メチル化酵素LSD1に対する高選択的阻害剤NCL1は有害事象なく前立腺癌を抑制する2017

    • Author(s)
      惠谷 俊紀
    • Organizer
      日本アンドロロジー学会第36回学術集会
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] エピゲノム変化を介した去勢抵抗性前立腺癌におけるオートファジー制御メカニズムの解明と新規治療法の開発2017

    • Author(s)
      内木 拓、惠谷 俊紀、内木 綾、飯田 啓太郎、河合 憲康、安井 孝周、髙橋 智
    • Organizer
      第33回前立腺シンポジウム
    • Related Report
      2017 Research-status Report
    • Invited
  • [Presentation] Lysine specific demethylase 1 inhibitors and autophagy inhibitor suppresses castration resistant prostate cancer growth.2016

    • Author(s)
      Etani Toshiki, Naiki Taku, Iida Keitaro, Ando Ryosuke, Kawai Noriyasu, Tozawa Keiichi, Suzuki Takayoshi, Takahashi Satoru, Yasui Takahiro
    • Organizer
      第75回日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜(神奈川県横浜市)
    • Year and Date
      2016-10-06
    • Related Report
      2016 Research-status Report
  • [Presentation] Novel selective lysine‐specific demethylase 1 inhibitors and autophagy inhibitors effectively impair castration‐resistant prostate cancer growth.2016

    • Author(s)
      Etani Toshiki, Naiki Taku, Suzuki Takayoshi, Nagai Takashi, Iida Keitaro, Ando Ryosuke, Kawai Noriyasu, Tozawa Keiichi, Mogami Tohru, Kohri Kenjiro, Yasui Takahiro
    • Organizer
      American Urological Association Annual Meeting 2016
    • Place of Presentation
      San Diego, USA
    • Year and Date
      2016-05-06
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] 去勢抵抗性前立腺癌に対するヒストン脱メチル化酵素阻害剤の治療効果2016

    • Author(s)
      惠谷 俊紀、内木 拓、永井 隆、飯田 啓太郎、安藤 亮介、河合 憲康、戸澤 啓一、最上 徹、郡 健二郎、鈴木 孝禎、安井 孝周
    • Organizer
      第104回日本泌尿器科学会総会
    • Place of Presentation
      仙台国際センター他(宮城県仙台市)
    • Year and Date
      2016-04-23
    • Related Report
      2016 Research-status Report
  • [Presentation] ヒストン脱メチル化酵素LSD1の新規阻害剤NCL1の前立腺癌に対する抗腫瘍効果2016

    • Author(s)
      惠谷 俊紀、内木 拓、飯田 啓太郎、安藤 亮介、河合 憲康、戸澤 啓一、鈴木 孝禎、高橋 智、安井 孝周
    • Organizer
      第67回名古屋市立大学医学会総会
    • Place of Presentation
      名古屋市立大学(愛知県名古屋市)
    • Related Report
      2016 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi